WASHINGTON (AP) — Federal regulators are challenging patents on 20 brand name drugs, including the blockbuster weight-loss injection Ozempic, in the latest action by the Biden administration targeting industry practices that drive up pharmaceutical prices.
The Federal Trade Commission on Tuesday sent warning letters to 10 drugmakers, taking issue with patents on popular drugs for weight loss, diabetes, asthma and other reparatory conditions. The letters allege that certain patents filed by Novo Nordisk, GlaxoSmithKline, AstraZeneca and seven other companies are inaccurate or misleading.
Brand-name drugmakers use patents to protect their medicines and stave off cheaper, generic medicines. Most blockbuster drugs are protected by dozens of patents covering various ingredients, manufacturing processes and intellectual property. Generic drugmakers can only launch their own cheaper versions if the patents have expired or are successfully challenged in court.
Related articles:
Related suggestion:
Kenya president postpones reopening of schools as floodDenmark to liberalize its abortion law to allow the procedure until 18th week of pregnancyAnchovies draw crush of sea lions to San Francisco piers, the most in 15 yearsFrench cyberwarriors ready to test their defense against hackers and malware during the OlympicsWhoopi Goldberg reveals who will get her $60 MILLION fortune when she diesFloyd Mayweather gifts $30k to homeless men before ClippersTroops fired on Kent State students in 1970. Survivors see echoes in today's campus protestsA Black lawmaker briefly expelled from the Tennessee Statehouse will remain on the 2024 ballotAnthony Edwards and the TLawyers for teen suing NBA star Ja Morant over a fight during a pickup game withdraw from the case
2.6263s , 6500.890625 kb
Copyright © 2024 Powered by US challenges 'bogus' patents on Ozempic and other drugs in effort to spur competition ,Horizon Herald news portal